Aug 29, 2026
ManyPress

Advertisement

Health

A new experimental blood test called DENEB has shown high sensitivity for detecting early-stage colorectal cancer and precancerous polyps in a recent multicenter study.

ManyPress

ManyPress

ManyPress Editorial

3 min readSource:Healthline
Experimental Blood Test Shows Promise in Detecting Precancerous Polyps

Key facts

  • The DENEB blood test detected 92% of stage I–III colorectal cancers and 81% of high-risk polyps in a study of over 1,500 adults.
  • The study was published in The Lancet Gastroenterology & Hepatology on August 10.
  • Colorectal cancer is the second leading cause of cancer death in the United States.
  • The FDA-approved Shield blood test is approximately 13% effective at detecting precancerous polyps.
  • A separate study published in JAMA Network on August 20 indicated that screening can lower the risk of dying from colorectal cancer by up to 43%.

A new experimental blood test, DENEB, has demonstrated the ability to detect early-stage colorectal cancer and precancerous polyps in a multicenter study published in The Lancet Gastroenterology & Hepatology. Researchers found the test identified 92% of stage I–III colorectal cancers and 81% of high-risk polyps in a trial of over 1,500 adults. While promising, experts note that more research is required before the test can be recommended for routine clinical screening.

By the numbers

92%
detection rate for stage I–III colorectal cancers
81%
detection rate for high-risk precancerous polyps
1,500
adults participating in the study
13%
Shield test effectiveness for detecting precancerous polyps
43%
reduced risk of death from screening

Study Findings and Methodology

The study, which included participants from China, Japan, and Spain, evaluated the DENEB test's performance against traditional screening methods. In addition to its high detection rate for stage I–III cancers, the test identified 91% of colorectal cancers overall. Researchers highlighted that the test's ability to detect precancerous polyps is a significant advancement, as removing these lesions can prevent cancer from developing.

Comparison to Existing Screening Methods

Colonoscopy and stool-based tests remain the gold standard for colorectal cancer screening. While other blood-based tests like Shield are currently available and FDA-approved, they are generally less effective at detecting precancerous polyps, with Shield showing approximately 13% effectiveness in that area. Experts emphasize that DENEB is not intended to replace colonoscopies, which remain the definitive method for both finding and removing lesions.

Clinical Implications

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in the United States. With rates rising among individuals under 50, researchers are seeking more accessible screening options to encourage participation. A blood test could potentially be integrated into routine medical visits to identify patients who require further diagnostic procedures like a colonoscopy.

Advertisement

This article was independently rewritten by ManyPress editorial AI from reporting originally published by Healthline.

Health